- Conditions
- Diabetes With Diabetic Retinopathy With Macular Edema
- Interventions
- Vitrectomy
- Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 944
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Prostate Cancer, Insulin Resistance
- Interventions
- Pioglitazone 30 mg, placebo tablet
- Drug
- Lead sponsor
- St. Louis University
- Other
- Eligibility
- 18 Years to 85 Years · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Diabetic Neuropathy, Painful
- Interventions
- pregabalin (Lyrica), Placebo
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 633 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 150
- States / cities
- Birmingham, Alabama • Northport, Alabama • Gilbert, Arizona + 120 more
- Conditions
- Chronic Kidney Disease
- Interventions
- collection of serum/capillary creatinine values
- Diagnostic Test
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 223 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 19
- States / cities
- Huntsville, Alabama • Victorville, California • Bloomfield, Connecticut + 14 more
- Conditions
- Foot Ulcer, Diabetic
- Interventions
- GrafixPRIME®, Dressing Application, Off-loading (walking boot)
- Other · Procedure · Device
- Lead sponsor
- Osiris Therapeutics
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 3
- States / cities
- Arizona City, Arizona • California City, California • New Mexico, New Mexico
- Conditions
- Diabetic Foot, Quality of Life, Mental Health Wellness 1, Ulcer Foot, Diabetes Complications
- Interventions
- No intervention, this is an observational study
- Other
- Lead sponsor
- Podimetrics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Somerville, Massachusetts
- Conditions
- Diabetic Neuropathy
- Interventions
- Pregabalin, Placebo
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Diabetic Peripheral Neuropathy
- Interventions
- Tapentadol extended release (ER), Placebo
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 60
- States / cities
- Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 57 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- BI 10773 placebo, BI 10773 low dose, BI 10773 high dose
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 494 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 50 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Pioglitazone 15 mg, Pioglitazone 45 mg, Pioglitazone 30 mg, Linagliptin 5mg / Pioglitazone 45 mg FDC, Linagliptin 5mg / Pioglitazone 30 mg FDC, Linagliptin 5mg, Linagliptin 5mg / Pioglitazone 15 mg FDC
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 936 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Muscle Shoals, Alabama + 60 more
- Conditions
- Hypertension, Diabetes Mellitus, Type 2
- Interventions
- telmisartan combined with hydrochlorothiazide (80/12.5 mg), valsartan combined with hydrochlorothiazide (160/12.5mg)
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 840 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 47 more
- Conditions
- Diabetic Retinopathy
- Interventions
- ruboxistaurin, placebo
- Drug
- Lead sponsor
- Chromaderm, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 685 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Diabetic Peripheral Neuropathy
- Interventions
- Arm A - Non-Diabetic, Gait and Balance
- Procedure
- Lead sponsor
- Foot Surgery Center of Northern Colorado
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2025
- U.S. locations
- 1
- States / cities
- Fort Collins, Colorado
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Hyperglycemia, Vaccine Adverse Reaction
- Interventions
- None (not interventional)
- Other
- Lead sponsor
- Levenson, David I., M.D.
- Individual
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Boca Raton, Florida
- Conditions
- Peripheral Artery Disease
- Interventions
- Fitbit Physical Activity Monitor, mHealth Glucometer, mHealth Blood Pressure
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Diabetic Retinopathy
- Interventions
- blood draw
- Biological
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 21 Years to 98 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Diabetes, Continuous Glucose Monitoring System
- Interventions
- Not listed
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 2 Weeks to 24 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide, exenatide extended-release, albiglutide, dulaglutide, Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 514 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 62 more
- Conditions
- Type 2 Diabetes Mellitus, Chronic Kidney Disease
- Interventions
- CTP-499, Placebo
- Drug
- Lead sponsor
- Concert Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 49
- States / cities
- Tempe, Arizona • Harrisburg, Arkansas • Little Rock, Arkansas + 38 more
- Conditions
- Diabetic Nephropathy
- Interventions
- VPI-2690B low dose, VPI-2690B medium dose, Placebo to match VPI-2690B, VPI-2690B high dose
- Drug
- Lead sponsor
- Vascular Pharmaceuticals, Inc.
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • La Mesa, California + 29 more
- Conditions
- Wound Healing, Diabetes
- Interventions
- Pulsatile Intravenous Insulin Therapy
- Procedure
- Lead sponsor
- Florida Atlantic University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Boca Raton, Florida
- Conditions
- Diabetes
- Interventions
- ATSM Intervention, GMV Intervention
- Behavioral
- Lead sponsor
- Agency for Healthcare Research and Quality (AHRQ)
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 339 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Allogeneic Cultured Islet Cells (human); Encapsulated
- Biological
- Lead sponsor
- Novocell
- Industry
- Eligibility
- 20 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 2
- States / cities
- San Antonio, Texas
- Conditions
- Diabetic Macular Edema(DME)
- Interventions
- YD312 50mg, YD312 150mg, YD312 350mg, Placebo
- Drug
- Lead sponsor
- YD Global Life Science Co., Ltd.
- Industry
- Eligibility
- 19 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Hialeah, Florida • Lakeland, Florida + 10 more